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Introduction
Since the first report [1] of intrapleural vacu-
um-assisted closure (VAC) therapy in 2006, many 
investigators have demonstrated the advantages 
and effectiveness of intrathoracic negative pressure 
therapy (INPT) in patients with complex empyema 
of various etiologies with or without bronchopleu-
ral fistulas (BPFs). The current European Association 
for Cardio-Thoracic Surgery expert consensus state-
ment [2] and the American Association for Thoracic 
Surgery guidelines for pleural empyema manage-
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A b s t r a c t
Introduction: Intrathoracic negative pressure therapy is an adjunct to standard methods of complex empyema man-
agement in debilitated patients. Nevertheless, the use of endoscopic one-way endobronchial valves to successfully 
close large bronchopleural fistulas in patients with advanced pleural empyema has been described in only a few case 
reports.
Aim: To present our experience in managing complex pleural empyema using thoracostomy with intrathoracic neg-
ative pressure therapy and/or endobronchial valve implantation.
Material and methods: We retrospectively analyzed data from 13 consecutive patients (11 men, mean age: 56 years, 
range: 38–80 years) who were treated for pleural empyema using thoracostomy with intrathoracic negative pressure 
therapy and/or endobronchial valve implantation between October 2015 and November 2017.
Results: The control of empyema was satisfactory in 12 patients; however, 1 patient died from sepsis-related multi-
organ failure despite complete cessation of air leak on day 9 after endobronchial valve implantation. The overall suc-
cess rate for the final closure of the chest wall was 9/12 patients (75%): in 5 patients, the wall closed spontaneously, 
and in 4, the wall was closed using thoracomyoplasty.
Conclusions: Thoracostomy with intrathoracic negative pressure therapy, endobronchial valve implantation with 
tube drainage, and a combination of the two could adequately manage patients with pleural empyema with or 
without a persistent air leakage fistula.
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ment [3] have established the role of intrathoracic 
VAC therapy as an adjunct to standard surgical treat-
ment methods for the management of complicated 
empyema with or without BPFs, especially in debil-
itated patients. Nevertheless, the use of one-way 
endobronchial valves (EBVs) for the successful clo-
sure of peripheral large air leaks in patients with ad-
vanced pleural empyema has been limited to a few 
case reports and small series [4]. 
Aim
We aimed to present our experience in managing 
complex pleural empyema using thoracostomy with 
intrathoracic negative pressure therapy and/or en-
dobronchial valve implantation.
Material and methods 
We retrospectively reviewed data from 13 con-
secutive patients (11 men) with a  mean age of 
56 years (range: 38–80 years) who were treated for 
pleural empyema using open, mini-, or tube-tho-
racostomy with INPT and/or with EBV implantation 
between October 2015 and November 2017; this 
sample constitutes all patients seen at our hos-
pital for this condition with this intervention. This 
study was approved by our institutional ethics com-
mittee, and written informed consent from the pa-
tients was waived as this is a  retrospective study, 
and these consents had been obtained from each 
patient before any surgery/invasive procedures were 
performed. Demographic and clinical characteristics 
of patients prior to the onset of the aforementioned 
treatments are summarized in Table I.
The majority of patients had stage III empyema 
(n = 9), central or peripheral BPFs (n = 11), and 
poor general condition with Karnofsky index ≤ 50% 
(n = 7), which made them unsuitable for major 
thoracic surgery. Eight (62%) patients had primary, 
3 (23%) had secondary, and 2 (15%) had recurrent 
etiologies of pleural empyema. 
EBVs were made from rubber composite material 
(MedLung, Barnaul, Russian Federation) [5]. Implan-
tation was performed either under general anesthe-
sia with a flexible bronchoscope inserted through an 
endotracheal tube during surgery or under moder-
ate sedation if valve implantation or correction of its 
malposition was done pre- or postoperatively.
The airway leading to the air leak was identified 
by instillation of 1% Viride nitens (brilliant green) 
solution diluted (1 : 30) with 3% hydrogen perox-
ide via the chest tube. After the visual assessment 
of the dyed bronchus diameter with endobronchial 
forceps of various sizes, EBV of diameter larger by 
2–3-mm of the bronchial diameter was advanced 
into the affected airway (Photo 1) while a marked 
decrease in air leak via the chest tube into the water 
seal chamber was achieved. 
Operative technique 
We performed open or video-assisted (VATS) tho-
racic surgical procedures consisting of pus evacua-
tion, debridement, local decortication, and BPF clo-
sure with direct interrupted sutures when applicable, 
as well as flushing of the cavity with saline through 
open window thoracostomy (OWT) after partial re-
section (5 cm) of two ribs or via the retracted orifice 
after closed tube thoracostomy. 
The pleural cavity was loosely filled with po-
vidone iodine-soaked gauze(s), which had been 
wrapped around a chest tube with lateral perfora-
tions, and closed with an adhesive film attached 
over the skin margins of the thoracostomy. Wall 
suction was set to apply intrathoracic negative 
pressure ranging from –75 to –150 mm Hg through 
the chest tube, previously placed using an addition-
al intercostal aperture or via the film. In clinically 
stable patients, the suction was alternated with 
water seal for 1 h but not for more than five times 
a day. Wound revisions and dressing changes were 
performed two-three times a week under moderate 
sedation. After inpatient culture-specific systemic 
antimicrobial therapy, patients with unclosed OWT/
wounds were treated with conventional wound care 
in outpatient settings.
Results
Treatment modalities with INPT and EBV implan-
tation as well as their outcomes are shown in Table II.
The control of empyema and sepsis was satis-
factory in 12 patients; however, 1 patient who was 
treated with EBV and drainage of the chest died of 
sepsis-related multiorgan failure, despite complete 
cessation of the air leak on day 9 after EBV implan-
tation. The median postoperative length of hospital 
stay for all patients, excluding the deceased patient, 
was 21 days (range: 13–182 days). BPF closure was 
achieved in all surviving patients, and the median 
time from the beginning of the therapy to air leak 
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resolution without thoracoplasty was 15 (7–21) days 
for the eight surviving patients. Moreover, in 2 pa- 
tients treated with thoracostomy-INPT and EBV 
implantation (Photo 2) (P10, P11) and in 1 patient 
with a  large peripheral BPF treated with thoracos-
tomy-INPT alone (P12), the pulmonary parenchyma 
re-expanded and the thoracic wall was closed spon-
taneously without thoracoplasty. 
The overall success rate for the final closure of 
the chest wall was 9/12 patients (75%): in 5 pa-
tients, the wall closed spontaneously over a median 
of 29 days (range: 14–250 days), and in 4 patients 
with thoracomyoplasty, the wall closed at a mean of 
229 days (range: 111–540 days) from the start of 
treatment with INPT and/or EBV implantation. None 
of the patients presented evidence of chronic/recur-
rent empyema at the 3-month outpatient follow-up 
after chest wall closure. One patient (P2) was not 
scheduled for wall closure because of cancer re-
currence. One patient (P3) refused closure of the 
OWT, and another 80-year-old patient (P6) rejected 
thoracostomy-INPT, thereby choosing to live with 
a  permanent thoracic wall defect/wound, chron-
ic mild-symptom empyema, and EBV left in place; 
nevertheless, there was no air leakage at a 7-month 
post-discharge follow-up.







Empyema onset  
days/stage
Preoperative microbiology  
of pleural fluid
P1 M/60 50% CANP, CT > 3000
III
Staphylococcus aureus
P2 M/48 70% SCLC, pneumonectomy, ChT, 
cancer recurrence, tracheopleural 
fistula 5 mm, chest wall phleg-




P3 M/62 70% CANP, CT, peripheral BPF, VATS 




P4 M/48 50% CANP, lower and middle lobe gan-




P5 F/69 < 50% Bullous disease, PTX, CT, periph-











P7 M/48 < 50% CANP, right lung gangrene, 






























P13 M/50 50% CANP, CT 54
III
Serratia species
P – patient, AI – antiseptic irrigation, BPF – bronchopleural fistula, CANP – community-acquired necrotizing pneumonia, COPD – chronic obstructive pulmo-
nary disease, ChT – chemotherapy, CT – chest tube, DBR – debridement, EBV – endobronchial one-way valve, INPT – intrathoracic negative pressure therapy, 
KI – Karnofsky index, PE – pulmonary embolism, PTX – pneumothorax, SCLC – small cell lung cancer, VATS – video-assisted thoracic surgery. 
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Discussion
It is well known that the surgical management of 
pleural empyema is a long-term and multi-step treat-
ment and is successful provided that the bronchop-
leural fistula is reliably closed in a  short period of 
time, especially with a minimally invasive approach, 
which significantly reduces perioperative stress and 
allows faster recovery after surgery [6]. 
In this study, a septic process was satisfactorily 
controlled in 12/13 (92%) patients with pleural em-
pyema using thoracostomy with INPT and/or EBV 
implantation; however, 1 patient died from sepsis-re-
lated multiorgan failure despite complete cessation 
of air leak after endobronchial valve implantation 
without INPT. The treatment experience of complex 
pleural empyema shown in this study encouraged us 
to develop an empyema treatment concept based on 
a combination of endobronchial implantation of uni-
lateral valves and negative pressure wound therapy 
for the complete evacuation of pus and maximum 
re-expansion of the lung parenchyma. We could not 
find any reports in the current literature describing 
this combination of simultaneous use of endobron-
chial one-way valves and thoracostomy (open and 
miniVATS) with vacuum-assisted closure/intratho-
racic negative pressure therapy for the spontaneous 
closure of the chest wall of patients with parapneu-
monic (patient 10) and posttraumatic (patient 11) 
pleural empyema with peripheral bronchopleural 
fistulas or large air leaks. 
In 2006, Varker and Ng [1] presented the first 
successful case of complete healing and closure 
of a  post-lobectomy empyema without BPF using 
a VAC device and recommended that the VAC device 
be tried for post-resectional empyema with or with-
out previously closed BPFs. 
Accelerated treatment of postpneumonectomy 
empyema developed by Schneiter et al. [7] consisted 
of repeated open surgical debridement of the pleu-
ral cavity and negative pressure wound therapy of 
the temporary closed chest cavity filled with povi-
done-iodine-soaked towels after closure and rein-
forcement of BPF, if present. This procedure resulted 
in 94.6% definitive closure of the cavity with an an-
tibiotic solution within 8 days.
Palmen et al. [8] showed that VAC treatment of 
recurrent empyema in the presence of the residu-
al lung tissue with or without alveolopleural fistu-
la achieved spontaneous OWT closure through the 
acceleration of tissue granulation. There was such 
significant improvement of the residual pulmonary 
parenchyma expansion that two debilitated patients 
were weaned from ventilator support because of 
pulmonary function improvements.
In 2011, Sziklavari et al. [9] described 2 cases of 
acute empyema with BPF treated using re-thora-
cotomy and pneumectomy/debridement with sub-
sequent closure of dehisced bronchial stumps with 
direct stitches, a pericardial flap, and OWT-VAC ther-
apy. Successful spontaneous closure was achieved 
in the case of the smaller recurrent BPF (1 mm); 
however, the larger one (8 mm) remained open, and 
the patient died of sepsis-related multiorgan failure 
despite the fact that his thoracic cavity was sterile 
during VAC therapy. 
The same group formulated the very important 
postulate that acute sepsis, failed primary surgical 
intervention, or its complications are indications 
for OWT and VAC intervention, and the presence of 
small BPFs and residual lung tissue is not a contra-
indication for VAC therapy. These authors also de-
veloped a  minimally invasive VAC therapy without 
classic OWT [10, 11] and presented the short- and 
long-term outcomes of three VAC techniques: OWT-
VAC, minimally invasive technique (Mini-VAC), and 
Photo 1. Proximal part with the falling petal 
valve of the rubber endobronchial prosthesis is 
seen, while its distal cylindrical part is implant-
ed in the affected upper segment of the left low-
er lobe (patient 10) 
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instillation (Mini-VAC-Instill) [12]. They concluded 
that the advantage of both minimally invasive mo-
dalities was the high rate of chest wall closure with-
in the same hospital stay (60%, 100%, and 87% re-
spectively) and that BPF is not a contraindication for 
VAC. Finally, they concluded that a  large BPF could 
be closed using a muscle or pericardium flap after 
OWT-VAC therapy.
Taken together, these data suggest that INPT is 
a safe and efficient adjunct to standard open or min-















Outcome of INPT 
and/or EBV
Chest wall closed 
(post-discharge 
day)







16 23/6 11 25 Empyema & BPF 
healed/OWT 
No
P3 OWT/DBR/INPT 21 11/3 21 24 Empyema & BPF 
healed/OWT 
No






P5 12 mm Ø EBV into 
LLL/CT/MV
9 N/A 18 18 Death due to 
sepsis
N/A
P6 12 mm Ø EBV  
into RLL/CT/MV = 
51 days







19 18/5 20 20 KI > 70%, 










P9 12 mm Ø EBV into 
RBI/CT
8 N/A 13 14 KI > 70%, 





P10 (1) 10 mm Ø EBV 
into LLL-B6/CT
(2) OWT/DBR/ 










P11 VATS-DBR/11 mm 
Ø EBV into RLL/
INPT 





P12 OWT/DBR/INPT 14 15/4 9 18 KI > 70%, 









P – patient, AIR – air leak resolution, BPF – bronchopleural fistula, CT – chest tube, DBR – debridement, EBV – endobronchial one-way valve, INPT – intratho-
racic negative pressure therapy, LLL – left lower lobe, KI – Karnofsky index, MV – mechanical ventilation, OWT – open window thoracostomy, LLL-B6 – superior 
segment of left lower lobe, RBI – right bronchus intermedius, RLL – right lower lobe, VATS – video-assisted thoracic surgery, N/A – not applicable. *EBV removed 
on post-discharge day 20, **EBV removed on post-discharge day 29.
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imally invasive/VATS surgery for the management 
of complex pleural empyema because it potentially 
reduces OWT-related mortality and morbidity and 
helps to avoid an OWT. It can be used as a bridge 
[13] for reconstructive surgery or for definitive clo-
sure of the empyema cavity depending on the eti-
ology, general condition of the patient, and current 
stage of disease [14], especially if large BPFs have 
been previously closed. 
The gold standard for the treatment of BPFs re-
mains surgery; however, treatment with EBV implan-
tation should be considered the first-line approach 
in high-risk patients or in cases where the surgical 
option has failed [15].
In 2005, Snell et al. [16] presented the first de-
scription of noninvasive successful treatment of 
a patient with a bronchocutaneous fistula persisting 
for 6 years following right upper lobotomy and tho-
racoplasty for aspergillomas using EBV unidirection-
al prosthesis, originally developed for the treatment 
of severe emphysema.
Subsequently, Schweigert et al. [17] described 
the successful treatment of 2 patients with para-
pneumonic empyema using EBV implantation to 
block the segmental bronchus leading to a persist-
ing peripheral BPF, occurring in both patients after 
minimally invasive VATS with pleural debridement.
In 2013, Gudbjartsson et al. [18] reported the 
successful implantation of EBVs into the B1 and B2 
segmental bronchi for the treatment of a  patient 
with BPF persisting for 6 months after surgical treat-
ment of necrotizing pneumonia. Mahajan et al. [19] 
described the successful use of EBV in the treatment 
of postpneumonectomy empyema with BPF in pa-
tients requiring mechanical ventilation. Kalatoudis 
et al. [20] reported a case where EBV implantation 
facilitated endotracheal extubation of a patient with 
a parapneumonic empyema, BPF, acute respiratory 
distress syndrome, and severe respiratory failure on 
prolonged mechanical ventilation. In general, very 
few cases of successful use of EBV with chest drain-
age in patients with empyema and BPF have been 
described, perhaps because this method is used 
only in empyema patients with a poor condition and 
very high surgical risk who are not suitable for pri-
mary major chest surgery or reoperation.
Two types of EBVs, the Zephyr EBV (Pulmonx, Red-
wood City, CA) and Spiration IBV (Olympus Respira-
tory America, Redmond, WA), are currently available 
in Europe and the United States [4], and one is avail-
able in the Russian Federation (MedLung, Barnaul, 
RU). Levin et al. [5] published the results of minimally 
invasive treatment of patients with destructive pul-
monary multidrug-resistant tuberculosis and showed 
Photo 2. A  – Computed tomography showing parapneumonic pleural empyema with atelectasis of the 
left lower lobe after endobronchial valve implantation into the segmental bronchus (B6) and chest tubes 
drainage (Patient 10). B – Chest radiography of this patient on day 29 post-discharge showing re-expansion 
of the lung after treatment by replacement of endobronchial valve in the left lower lobe and thoracostomy 
with intrathoracic negative pressure therapy
A B
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that EBV implantation led to faster bacteriological 
conversion, cavity closure, and reversible changes 
in the respiratory function, whereas the majority of 
patients (55%) had hypoventilation in the blocked 
lobe without complete atelectasis. In our opinion, 
this valve is preferable for the treatment of empy-
ema with BPFs because it was originally developed 
and tested to treat an infectious process, although 
not acute, in the bronchial tree, lungs, and pleura.
Most recently, Ding et al. [21] reviewed 34 case re-
ports and 10 case series comprising 208 patients with 
persistent air leaks of various etiology treated with 
EBVs. They found that complete resolution of air leaks 
was obtained within less than 24 h in the majority of 
patients (60%). In the present case series, complete 
resolution of the leak was not achieved within less 
than 7 days (7–21) during INPT and/or EBV implanta-
tion; however, we did not observe major complications 
related to EBV implantation and VAC therapy, includ-
ing bleeding from the lung or mediastinal structures 
or residual lung parenchymal atelectasis. Moreover, 
1 patient with poor condition was weaned from venti-
latory support over 51 days after EBV placement and 
on day 42 after the cessation of air leakage.
Despite the fact that the optimal treatment of 
empyema with BPF should be individualized, the 
basis goals of surgery for empyema, since Hippo-
crates of Kos (460–370 BC), were, are, and should be 
(1) full pus evacuation/debridement of the pleural 
cavity and (2) full lung expansion [14]. 
At the first glance, it is illogical to use a valve that 
reduces the air flow through the blocked pulmonary 
lobe, thereby inhibiting its re-expansion (the sec-
ond goal); on the other hand, our approach is based 
on the conclusion that INPT, probably with the help 
of collateral ventilation between lobes/segments, 
should compensate for the negative impact of the 
EBV blockage of lung expansion and should ensure 
complete postoperative evacuation (the first goal).
The combination of these two approaches makes 
it possible to (1) secure minimal invasive break of the 
vicious circle where a severe septic process is main-
tained by re-infection constantly repeated via fistula, 
in turn making it impossible to close the fistula us-
ing invasive methods, and (2) achieve essential lung 
parenchyma re-expansion and definitive healing 
without any additional surgical interventions. 
The main limitations of our study are its retro-
spective nature, the small number of patients with 
varying heterogeneous empyema and treatment 
modalities, which makes it impossible to match any 
true control group from our previous experience to 
compare the treatment results. Therefore, further 
studies are needed to evaluate the role of EBV and 
INPT combinations in the management of patients 
with complex empyema (stage II/III, recurrent/chron-
ic) and large BPF(s) and incomplete re-expansion of 
residual lung parenchyma. However, these limita-
tions do not reduce the importance and clinical rele-
vance of the proposed treatment modalities, and we 
believe that first-line options to manage these pa-
tients before major surgery, or if any other surgical 
option has failed, should be various combinations of 
debridement/decortication through thoracostomy 
(minimally invasive, VATS or open) with EBV implan-
tation before, within, or after the surgical procedures 
to resolve/decrease the air leak. Adjunct INPT/VAC 
therapy should be used to allow full/maximum re-
sidual/atelectatic parenchyma expansion and full 
evacuation. Furthermore, we agree with other au-
thors [9] that these alternative treatments should be 
discussed as soon as possible because spontaneous 
closure of the chest wall was achieved in the last 
5 patients in the relatively early stages of empyema.
Conclusions
Thoracostomy with intrathoracic negative pres-
sure therapy, endobronchial valve implantation with 
tube drainage, and a combination of the two could 
adequately manage patients with pleural empyema 
with or without a persistent air leakage fistula.
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